Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Universal Ibogaine Inc ( (TSE:IBO) ).
Universal Ibogaine Inc. has provided an update on its delayed year-end 2025 financial filings, confirming it remains under a management cease trade order after missing the November 28 deadline for its audited financial statements, MD&A, and related certifications. The company says completion of the audit, and thus the required filings, is tied to its ongoing restructuring and any necessary stock exchange approvals, and it will continue issuing mandated bi-weekly default status reports while in default. As part of the restructuring, Universal Ibogaine has temporarily closed its Kelburn Recovery Centre addiction treatment facility near Winnipeg and is pursuing financing options that may include the sale of all or part of the Kelburn property, with a portion of potential sale proceeds earmarked to fund completion of the audit. Following any such sale, management plans to concentrate resources on its core medical research business to advance ibogaine through a planned clinical trial application with Health Canada, signaling a strategic shift away from operating treatment centers toward a more research- and licensing-driven model.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine. The company is planning a Canadian clinical trial targeting opioid use disorder and ultimately aims to commercialize its treatment protocol globally via future licensing agreements.
Average Trading Volume: 600,321
Technical Sentiment Signal: Sell
Current Market Cap: C$2.75M
See more insights into IBO stock on TipRanks’ Stock Analysis page.